Hope Pharmaceuticals

Focus: Hope Pharmaceuticals is a specialty pharmaceutical company headquartered in Scottsdale, AZ focused on rare and critical-care indications, particularly cyanide poisoning treatment and emerging applications in neurology and hematology.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Hope Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Hope Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

1 in 5yr

SODIUM THIOSULFATE

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

NITHIODOTE

Acute cyanide poisoning (life-threatening)

Peak5.6yr

FDA-approved combination antidote for acute systemic cyanide poisoning with synergistic mechanism; unique market position in critical-care emergency medicine.

Help build intelligence for Hope Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Owns peak-lifecycle marquee product NITHIODOTE (sodium nitrite/sodium thiosulfate) for acute cyanide poisoning with LOE protection until 2031, providing revenue stability for the near term.
Diversified pipeline with 9 active clinical trials spanning Phase 1–3 programs in oncology, hemophilia, hematology, and neuroinflammatory indications, offering exposure to multiple therapeutic areas.
Rare-disease and critical-care focus enables deep clinical expertise and potential for high-impact interventions in underserved patient populations.

Watch Out For

No active job openings and no disclosed employee count or funding data suggest either early-stage constraints or minimal hiring momentum, creating limited career entry points.
Broad, unfocused pipeline (bortezomib, lenalidomide, erlotinib, risperidone repurposing) lacks clear therapeutic coherence and raises questions about resource allocation and internal prioritization.
Zero published research output and minimal public visibility make it difficult to assess clinical credibility or innovation leadership in competitive specialty pharma markets.